• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable

by Jasmine Pennic 08/06/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable,

What You Should Know: 

– A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal. 

– The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community’s views on the rapidly growing class of GLP-1 medications, often hailed as “miracle drugs” for weight loss. 

Key Findings Reveals Skepticism About Weight Loss Drugs

The key findings reveal significant concerns about the long-term efficacy, potential side effects, and overall impact of these medications on public health: 

– Doubtful about long-term efficacy: Most physicians believe GLP-1 medications are not sustainable beyond two to three years and should not be used as a long-term solution.

– Overprescription concerns: A large majority of physicians feel GLP-1s are being overprescribed and that lifestyle interventions should be prioritized.

– Need for stricter guidelines: Physicians advocate for increased oversight through prior authorization and greater provider involvement in prescribing decisions.

– Patient misconceptions: Many doctors report that patients have unrealistic expectations about the effectiveness and safety of GLP-1 medications.

– Potential for increased healthcare costs: The widespread adoption of GLP-1s is expected to drive up healthcare costs due to increased demand and limited supply.

– Concerns about health equity: Physicians are worried about the potential for increased health disparities as GLP-1 medications may not be equally accessible to all patients.

Alternative Approaches to Weight Management

The survey highlights the importance of comprehensive weight management programs that address both physical and psychological factors. Programs like Virta, which focuses on lifestyle changes and medical support, offer an alternative to medication-based approaches. By combining nutrition, exercise, and personalized coaching, Virta has helped patients achieve sustainable weight loss and improve overall health. The growing popularity of GLP-1 medications underscores the need for more rigorous research and data on their long-term effects and impact on public health. Healthcare providers must have access to comprehensive information to make informed decisions about treatment options for their patients.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Diabetes Management, Diabetes Management Platform, Diabetes Prevention Platform, GLP-1, Virta Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |